Milestone Pharmaceuticals (MIST) Accumulated Expenses (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Accumulated Expenses came in at $1.2 million in Q1 2026, little changed YoY from $1.2 million in Q1 2025, and down 84.9% on a QoQ basis from $7.6 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Accumulated Expenses (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Accumulated Expenses data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Accumulated Expenses changed 0.43% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed 0.43% YoY) and the FY2025 annual result came in at $7.6 million, up 205.64% from the prior year.
- Accumulated Expenses eased to $1.2 million in Q1 2026, from $7.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $7.6 million in Q4 2025 to a low of $527000.0 in Q2 2022.
- A 5-year average of $1.9 million and a median of $1.9 million in 2022 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 258.06% in 2023, down 72.33% in 2023.
- Tracing MIST's Accumulated Expenses over 5 years: stood at $2.6 million in 2022, then tumbled by 72.33% to $712000.0 in 2023, then surged by 251.26% to $2.5 million in 2024, then jumped by 205.64% to $7.6 million in 2025, then plunged by 84.9% to $1.2 million in 2026.
- The last three Accumulated Expenses figures came in at $1.2 million (Q1 2026), $7.6 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.98 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 7.64 Mn |
| Sep 30, 2025 | 2.41 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 824,000.00 |
| Dec 31, 2023 | 712,000.00 |
| Sep 30, 2023 | 2.43 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 2.57 Mn |
| Sep 30, 2022 | 1.85 Mn |
| Jun 30, 2022 | 527,000.00 |
| Mar 31, 2022 | 528,000.00 |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2021 | 1.02 Mn |